NCT05531279View on ClinicalTrials.gov

A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency

NARecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 5, 2022

Primary Completion Date

June 5, 2025

Study Completion Date

January 5, 2026

Conditions
Severe Aplastic Anemia
Interventions
DRUG

PEG-rhG-CSF

PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER